Aurobindo Pharma’s wholly owned subsidiary -- CuraTeQ Biologics has received Notice of Compliance (NOC) from Health Canada’s Biologics and Radiopharmaceutical Drugs Directorate (BRDD) for Bevqolva, its bevacizumab biosimilar. Health Canada issues an NOC after a successful review, granting formal marketing authorization to the biosimilar by confirming it meets regulatory standards for safety, efficacy, and quality - comparable to the reference biologic drug under the Food and Drug Regulations.

Bevacizumab, a humanized monoclonal antibody, inhibits angiogenesis - the formation of new blood vessels - by blocking vascular endothelial growth factor A (VEGF-A). This action slows tumor vascular growth and treats multiple cancers, including colorectal and lung. Available in 100 mg and 400 mg formulations, the originator product Avastin is marketed by Roche/Genentech.

In 2025, Bevqolva secured marketing authorization from the MHRA and launched commercially for patients across the UK. The product is currently under review by the CHMP with the European Medicines Agency. CuraTeQ Biologics also has two additional biosimilar applications under review by Health Canada.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.